Panacos Pharmaceuticals, Inc. (NASDAQ: PANC)
Panacos Pharmaceuticals is developing the next generation of antiviral drugs for the treatment of Human Immunodeficiency Virus (HIV) infection and other major viral diseases. The company's proprietary discovery technologies focus on novel targets in the virus life cycle, including the first and last steps of virus infection.
The first step in infection is Fusion of a virus particle to a human cell, an important new target for drug development. Panacos has a leading position in this area based on its scientists’ proven expertise in fusion inhibitor discovery, combined with powerful technologies to identify novel, orally available drug candidates.
The last step in the virus life cycle is virus Maturation, when the internal structure of a newly released virus particle is assembled. Panacos’ lead HIV inhibitor, PA-457, is the first in a new class of HIV drug candidates that act at this stage in the virus life cycle. By blocking virus maturation, PA-457 treatment prevents the spread of HIV infection to new cells.
| Company | Panacos Pharmaceuticals, Inc. (NASDAQ: PANC) |
|---|---|
| URL | http://www.panacos.com/ |
Vitex Closes Merger with Panacos Pharmaceuticals $20 Million Financing Also Closed and Funded
Watertown, MA (March 11, 2005) - V.I. Technologies, Inc. (Nasdaq: VITX) (“Vitex" or “the Company"), a biotechnology company dedicated to developing the next generation of anti-infective therapeutics, today announced that it has closed its prev...
Gaithersburg MD, January 6, 2005 /PRNewswire/ -- Panacos Pharmaceuticals, Inc., today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for PA-457, the Company’s once-daily oral drug candidate for the ...
Panacos Pharmaceuticals Announces Initiation of Phase 2 Clinical Development of its HIV Drug Candidate, PA-457
GAITHERSBURG, MD, December 10, 2004 /PRNewswire/ -- Panacos Pharmaceuticals, Inc. today announced the initiation of a Phase 2a clinical trial of PA-457, the first in a new class of HIV drug candidates called Maturation Inhibitors. Institution...
GAITHERSBURG, MD, November 29, 2004 /PRNewswire/ -- Panacos Pharmaceuticals, Inc. today announced that the terms of its proposed merger agreement with V. I. Technologies (Nasdaq: VITX), ("Bitex"), have been modified, following recent changes i...
HIV Drug Candidate, PA-457, Exhibits Potent Anti-HIV Activity Following a Single Dose in HIV-infected Patients
Full Results to be Presented at the 12th Conference on Retroviruses and Opportunistic Infections, February 2005
Additional Panacos presentations include data on PA-457's molecular target and the discovery of novel HIV fusion inhibitors
Panacos Pharmaceuticals to Present Phase 1 Data on its Lead HIV-1 Drug Candidate, PA-457, at XV International AIDS Conference, Bangkok, Thailand
GAITHERSBURG, MD, May 18, 2004 /PRNewswire/ -- Panacos Pharmaceuticals, Inc. today announced that it has closed a $18,300,000 Series C financing led by prior investors Ampersand Ventures and A. M. Pappas & Associates. New investors in this ro...
06/17/2008 | Taro InabaBoehringer Ingelheim announced an agreement to acquire Actimis Pharmaceuticals, Inc. one of our portfolio firms.
11/01/2007 | Nobuhiro Shimizu【Announcement of the Establishment of Beijing Office】
We are pleased to announce that Mitsui Ventures has opened a new office in Beijing in September2007.
07/18/2007 | Taro InabaMitsui Ventures Launching a New Approach to Seed Financing